Potential impact and challenges associated with Parkinson's disease patient care amidst the COVID-19 global pandemic.
COVID-19
Parkinson’s disease
Patient care
Telemedicine
Journal
Journal of clinical movement disorders
ISSN: 2054-7072
Titre abrégé: J Clin Mov Disord
Pays: England
ID NLM: 101662043
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
06
2020
accepted:
29
07
2020
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
13
8
2020
Statut:
epublish
Résumé
COVID-19 has made itself known to health care providers and families across the world in a matter of months. While primarily a respiratory disorder, it has also been shown to cause neurological symptoms, which can be a concern for Parkinson's disease (PD) patients. Although PD is not as common as other conditions such as cardiovascular diseases, it affects millions of patients around the world whose care has been affected by the global pandemic. The aim of this review is to provide insight into the direct and indirect associations between COVID-19 and PD patient care. Potential direct effects of COVID-19 include possible neurodegeneration, concerns of symptom self-management with over-the-counter (OTC) products and ICU challenges that can arise in PD patients. In addition, a subset of PD patients may be at higher risk of severe COVID-19 infection. The indirect effects of the pandemic are associated with the social distancing measures and disruptions in health care systems and PD clinical trials, which may negatively affect PD patients' mental wellbeing and create barriers in controlling their PD symptoms. On a more positive note, telemedical care is quickly emerging as a primary communication tool for virtual patient care. However, further research should be conducted to examine the applicability of telemedicine across the entire PD population, such as those with more severe symptoms living in less developed areas. With all the uncertainty during this time, it is hopeful to hear many promising COVID-19 treatments being researched, one of them being a PD drug therapy, amantadine. Hopefully, we can consider this pandemic an opportunity to strengthen the PD community and learn more about the impact of the SARS-COV-2 virus. This review provides an overview of the interaction between COVID-19 and PD patients and future investigational retrospective studies are suggested to validate the observations.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 has made itself known to health care providers and families across the world in a matter of months. While primarily a respiratory disorder, it has also been shown to cause neurological symptoms, which can be a concern for Parkinson's disease (PD) patients. Although PD is not as common as other conditions such as cardiovascular diseases, it affects millions of patients around the world whose care has been affected by the global pandemic.
OBJECTIVES
OBJECTIVE
The aim of this review is to provide insight into the direct and indirect associations between COVID-19 and PD patient care.
RESULTS
RESULTS
Potential direct effects of COVID-19 include possible neurodegeneration, concerns of symptom self-management with over-the-counter (OTC) products and ICU challenges that can arise in PD patients. In addition, a subset of PD patients may be at higher risk of severe COVID-19 infection. The indirect effects of the pandemic are associated with the social distancing measures and disruptions in health care systems and PD clinical trials, which may negatively affect PD patients' mental wellbeing and create barriers in controlling their PD symptoms. On a more positive note, telemedical care is quickly emerging as a primary communication tool for virtual patient care. However, further research should be conducted to examine the applicability of telemedicine across the entire PD population, such as those with more severe symptoms living in less developed areas. With all the uncertainty during this time, it is hopeful to hear many promising COVID-19 treatments being researched, one of them being a PD drug therapy, amantadine.
CONCLUSION
CONCLUSIONS
Hopefully, we can consider this pandemic an opportunity to strengthen the PD community and learn more about the impact of the SARS-COV-2 virus. This review provides an overview of the interaction between COVID-19 and PD patients and future investigational retrospective studies are suggested to validate the observations.
Identifiants
pubmed: 32782815
doi: 10.1186/s40734-020-00089-4
pii: 89
pmc: PMC7414276
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsI know of no conflict of interest with this publication, and there has been no financial support for this work that could have influenced the outcome.
Références
Mov Disord. 2020 Jun;35(6):905-908
pubmed: 32347572
Mov Disord. 2020 Jun;35(6):911
pubmed: 32320498
Mov Disord. 2020 Jul;35(7):1089-1093
pubmed: 32484584
Parkinsonism Relat Disord. 2013 Feb;19(2):218-21
pubmed: 23102808
J Parkinsons Dis. 2020;10(2):351-354
pubmed: 32250324
Mult Scler Relat Disord. 2020 Jul;42:102163
pubmed: 32388458
CNS Neurosci Ther. 2017 Mar;23(3):209-215
pubmed: 28071873
Mov Disord. 2020 Aug;35(8):1287-1292
pubmed: 32449528
J Neural Transm (Vienna). 2017 Aug;124(8):901-905
pubmed: 28150045
Tremor Other Hyperkinet Mov (N Y). 2020 Feb 17;10:
pubmed: 32195039
BMC Neurol. 2017 Jul 1;17(1):126
pubmed: 28666413
Parkinsonism Relat Disord. 2015 Aug;21(8):996-8
pubmed: 25997864
Stereotact Funct Neurosurg. 2017;95(3):174-182
pubmed: 28571034
J Med Virol. 2020 Jun;92(6):552-555
pubmed: 32104915
Mov Disord. 2020 Jul;35(7):1097-1099
pubmed: 32428342
J Parkinsons Dis. 2019;9(2):401-404
pubmed: 31127732
Parkinsonism Relat Disord. 2020 Jun;75:126-127
pubmed: 32414669
Curr Geriatr Rep. 2020 Jun;9(2):72-81
pubmed: 32509504
Neurol Neurochir Pol. 2020;54(2):204-206
pubmed: 32323862
Ann Indian Acad Neurol. 2020 Apr;23(Suppl 1):S24-S27
pubmed: 32419750
Telemed J E Health. 2019 Jul;25(7):541-550
pubmed: 30136898
Semin Neurol. 2003 Dec;23(4):351-63
pubmed: 15088256
Int J Antimicrob Agents. 2020 Jun;55(6):106004
pubmed: 32361028
Annu Int Conf IEEE Eng Med Biol Soc. 2015;2015:186-9
pubmed: 26736231
Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:1358-61
pubmed: 25570219
Mov Disord Clin Pract. 2020 May 04;7(4):361-372
pubmed: 32373652
Exp Neurol. 2012 Jan;233(1):79-86
pubmed: 22001159
J Mov Disord. 2020 May;13(2):105-114
pubmed: 32344993
Mov Disord Clin Pract. 2020 Apr 16;7(4):357-360
pubmed: 32373651
J Parkinsons Dis. 2020;10(3):911-913
pubmed: 32417800